<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29953326</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunotherapy of Guillain-Barré syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>2568</StartPage>
          <EndPage>2579</EndPage>
          <MedlinePgn>2568-2579</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2018.1493415</ELocationID>
        <Abstract>
          <AbstractText>Guillain-Barré syndrome (GBS), the most common cause of acute neuromuscular weakness and paralysis worldwide, encompasses a group of acute immune-mediated disorders restricted to peripheral nerves and roots. Immune-mediated attack of peripheral nervous system myelin, axons or both is presumed to be triggered by molecular mimicry, with both cell- and humoral-dependent mechanisms implicated in disease pathogenesis. Good circumstantial evidence exists for a pathogenic role for molecular mimicry in GBS pathogenesis, especially with its axonal forms, providing insights that could guide future immunotherapy. Intravenous immunoglobulin (IVIg) and plasma exchange (PE) are the most commonly prescribed immunotherapies for GBS with variable efficacy dependent on GBS subtype, severity at initial presentation and other clinical and electrophysiologic prognostic factors. The mechanisms of action of IVIg and PE are not known definitely. Despite recent significant advances in molecular biology that provide insights into GBS pathogenesis, no advances in therapeutics or significant improvements in patient outcomes have occurred over the past three decades. We summarize the clinical aspects of GBS, its current pathogenesis and immunotherapy, and highlight the potential of leukocyte trafficking inhibitors as novel disease-specific immunotherapeutic drugs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>a Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology , University of Alabama at Birmingham , Birmingham , AL , USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Division of Neurology , The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine , Tianjin , Peoples' Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dong</LastName>
            <ForeName>Chaoling</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>a Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology , University of Alabama at Birmingham , Birmingham , AL , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ubogu</LastName>
            <ForeName>Eroboghene Ekamereno</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
              <Affiliation>a Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology , University of Alabama at Birmingham , Birmingham , AL , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002634" MajorTopicYN="N">Chemotaxis, Leukocyte</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010951" MajorTopicYN="Y">Plasma Exchange</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Blood-Nerve Barrier</Keyword>
        <Keyword MajorTopicYN="Y">Guillain-Barré syndrome</Keyword>
        <Keyword MajorTopicYN="Y">Immunopathology</Keyword>
        <Keyword MajorTopicYN="Y">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">Leukocyte Trafficking</Keyword>
        <Keyword MajorTopicYN="Y">Peripheral Nerve Inflammation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29953326</ArticleId>
        <ArticleId IdType="pmc">PMC6314401</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2018.1493415</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Guillain G, Barre JA, Strohl A.
[Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916]. Ann Med Interne (Paris). 1999;150:24–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10400560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A prospective study on the incidence and prognosis of Guillain-Barre syndrome in Emilia-Romagna region, Italy (1992-1993) 
Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Neurology. 1997; 48:214–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9008520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Rees JH.
Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis. 1997;176(Suppl 2):S92–8. doi:10.1086/513793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/513793</ArticleId>
            <ArticleId IdType="pubmed">9396689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alshekhlee A, Hussain Z, Sultan B, Katirji B.
Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70:1608–13. doi:10.1212/01.wnl.0000310983.38724.d4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000310983.38724.d4</ArticleId>
            <ArticleId IdType="pubmed">18443311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sejvar JJ, Baughman AL, Wise M, Morgan OW.
Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33. doi:10.1159/000324710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000324710</ArticleId>
            <ArticleId IdType="pmc">PMC5703046</ArticleId>
            <ArticleId IdType="pubmed">21422765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meche FG.
Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000;54:620–5. doi:10.1212/WNL.54.3.620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.54.3.620</ArticleId>
            <ArticleId IdType="pubmed">10680793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R, et al. . 
Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:1146–50. doi:10.1212/01.WNL.0000055091.96905.D0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000055091.96905.D0</ArticleId>
            <ArticleId IdType="pubmed">12682322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogliun G, Beghi E, Italian GBSRSG.
Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand. 2004;110:100–6. doi:10.1111/j.1600-0404.2004.00272.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2004.00272.x</ArticleId>
            <ArticleId IdType="pubmed">15242417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG, Centre GB-cgotDNRS. Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur Neurol. 2001;45:133–9. doi:10.1159/000052111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000052111</ArticleId>
            <ArticleId IdType="pubmed">11306855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlikowski D, Prigent H, Sharshar T, Lofaso F, Raphael JC.
Respiratory dysfunction in Guillain-Barre Syndrome. Neurocrit Care. 2004;1:415–22. doi:10.1385/NCC:1:4:415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1385/NCC:1:4:415</ArticleId>
            <ArticleId IdType="pubmed">16174943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper AH, Wijdicks EFM, Truax BT.
Guillain-Barré syndrome. Philadelphia: F.A. Davis, 1991.</Citation>
        </Reference>
        <Reference>
          <Citation>Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, et al. . 
Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75:1439–47. doi:10.1212/WNL.0b013e3181f88345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181f88345</ArticleId>
            <ArticleId IdType="pubmed">20861454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST.
Guillain-Barre syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry. 1997;63:494–500. doi:10.1136/jnnp.63.4.494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.63.4.494</ArticleId>
            <ArticleId IdType="pmc">PMC2169759</ArticleId>
            <ArticleId IdType="pubmed">9343130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA.
Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82. doi:10.1038/nrneurol.2014.121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2014.121</ArticleId>
            <ArticleId IdType="pubmed">25023340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walgaard C, Jacobs BC, van Doorn PA.
Emerging drugs for Guillain-Barre syndrome. Expert Opin Emerg Drugs. 2011;16:105–20. doi:10.1517/14728214.2011.531699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14728214.2011.531699</ArticleId>
            <ArticleId IdType="pubmed">21352072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frenzen PD.
Economic cost of Guillain-Barre syndrome in the United States. Neurology. 2008;71:21–7. doi:10.1212/01.wnl.0000316393.54258.d1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000316393.54258.d1</ArticleId>
            <ArticleId IdType="pubmed">18591502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Arnason BG, Adams RD.
The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore). 1969;48:173–215. doi:10.1097/00005792-196905000-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-196905000-00001</ArticleId>
            <ArticleId IdType="pubmed">5769741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prineas JW.
Acute idiopathic polyneuritis. An electron microscope study. Lab Invest. 1972;26:133–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5059983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. . 
An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109(Pt 6):1115–26. doi:10.1093/brain/109.6.1115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/109.6.1115</ArticleId>
            <ArticleId IdType="pubmed">3790970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. . 
Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333–42. doi:10.1002/ana.410330402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410330402</ArticleId>
            <ArticleId IdType="pubmed">8489203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, et al. . 
Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39:17–28. doi:10.1002/ana.410390105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410390105</ArticleId>
            <ArticleId IdType="pubmed">8572662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. . 
Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol. 1998;44:780–8. doi:10.1002/ana.410440512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410440512</ArticleId>
            <ArticleId IdType="pubmed">9818934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, et al. . 
Antiganglioside antibodies are associated with axonal Guillain-Barre syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry. 2012;83:23–8. doi:10.1136/jnnp-2011-300309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-300309</ArticleId>
            <ArticleId IdType="pubmed">22010183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. . 
Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7600081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwabara S, Yuki N.
Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol. 2013;12:1180–8. doi:10.1016/S1474-4422(13)70215-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(13)70215-1</ArticleId>
            <ArticleId IdType="pubmed">24229616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JK, Bae JS, Kim DS, Kusunoki S, Kim JE, Kim JS, et al. . 
Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barre syndrome in Korea: a nationwide multicenter study. J Clin Neurol. 2014;10:94–100. doi:10.3988/jcn.2014.10.2.94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2014.10.2.94</ArticleId>
            <ArticleId IdType="pmc">PMC4017025</ArticleId>
            <ArticleId IdType="pubmed">24829594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S.
Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology. 2003;61:471–4. doi:10.1212/01.WNL.0000081231.08914.A1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000081231.08914.A1</ArticleId>
            <ArticleId IdType="pubmed">12939419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, Herbrink P, et al. . 
Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology. 2010;74:581–7. doi:10.1212/WNL.0b013e3181cff735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181cff735</ArticleId>
            <ArticleId IdType="pubmed">20157160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher M.
An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57–65. doi:10.1056/NEJM195607122550201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM195607122550201</ArticleId>
            <ArticleId IdType="pubmed">13334797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T.
Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104–6. doi:10.1212/WNL.56.8.1104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.56.8.1104</ArticleId>
            <ArticleId IdType="pubmed">11320188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper AH.
Unusual clinical variants and signs in Guillain-Barre syndrome. Arch Neurol. 1986;43:1150–2. doi:10.1001/archneur.1986.00520110044012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1986.00520110044012</ArticleId>
            <ArticleId IdType="pubmed">2946281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper AH.
Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994;51:671–5. doi:10.1001/archneur.1994.00540190051014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1994.00540190051014</ArticleId>
            <ArticleId IdType="pubmed">8018039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakerley BR, Yuki N.
Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–44. doi:10.1136/jnnp-2013-305397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2013-305397</ArticleId>
            <ArticleId IdType="pubmed">23804237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Cornblath DR.
Guillain-Barre syndrome. Lancet. 2005;366:1653–66. doi:10.1016/S0140-6736(05)67665-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)67665-9</ArticleId>
            <ArticleId IdType="pubmed">16271648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC.
Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 2014;137:33–43. doi:10.1093/brain/awt285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awt285</ArticleId>
            <ArticleId IdType="pubmed">24163275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakerley BR, Uncini A, Yuki N, Group GBSC, Group GBSC.
Guillain-Barre and Miller Fisher syndromes–new diagnostic classification. Nat Rev Neurol. 2014;10:537–44. doi:10.1038/nrneurol.2014.138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2014.138</ArticleId>
            <ArticleId IdType="pubmed">25072194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N.
Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis. 2001;1:29–37. doi:10.1016/S1473-3099(01)00019-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(01)00019-6</ArticleId>
            <ArticleId IdType="pubmed">11871407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Hartung HP.
Guillain-Barre syndrome. N Engl J Med. 2012;366:2294–304. doi:10.1056/NEJMra1114525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1114525</ArticleId>
            <ArticleId IdType="pubmed">22694000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, et al. . 
Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol. 1994;36:791–3. doi:10.1002/ana.410360517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410360517</ArticleId>
            <ArticleId IdType="pubmed">7526777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, et al. . 
The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51:1110–5. doi:10.1212/WNL.51.4.1110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.51.4.1110</ArticleId>
            <ArticleId IdType="pubmed">9781538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix JC, Raphael JC, Durand MC, et al. . 
Guillain-Barre syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52:837–44. doi:10.1093/cid/cir074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cir074</ArticleId>
            <ArticleId IdType="pubmed">21427390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrogan A, Madle GC, Seaman HE, de Vries CS.
The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150–63. doi:10.1159/000184748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000184748</ArticleId>
            <ArticleId IdType="pubmed">19088488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson BR, Zegarra JA, Lopez-Gatell H, Sejvar J, Arzate F, Waterman S, et al. . 
Binational outbreak of Guillain-Barre syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. Epidemiol Infect. 2014;142:1089–99. doi:10.1017/S0950268813001908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0950268813001908</ArticleId>
            <ArticleId IdType="pmc">PMC6527315</ArticleId>
            <ArticleId IdType="pubmed">23924442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heikema AP, Islam Z, Horst-Kreft D, Huizinga R, Jacobs BC, Wagenaar JA, et al. . 
Campylobacter jejuni capsular genotypes are related to Guillain-Barre syndrome. Clin Microbiol Infect. 2015;21:852 e1-9. doi:10.1016/j.cmi.2015.05.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2015.05.031</ArticleId>
            <ArticleId IdType="pubmed">26070960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, Drenthen J, Unger WWJ, Jacobs E, et al. . 
Intrathecal antibody responses to GalC in Guillain-Barre syndrome triggered by Mycoplasma pneumoniae. J Neuroimmunol. 2018;314:13–6. doi:10.1016/j.jneuroim.2017.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.11.011</ArticleId>
            <ArticleId IdType="pubmed">29301655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visser LH, van der Meche FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. . 
Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group. Neurology. 1996;47:668–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8797462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taheraghdam A, Pourkhanjar P, Talebi M, Bonyadi M, Pashapour A, Sharifipour E, et al. . 
Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barre syndrome. Iran J Neurol. 2014;13:7–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3968351</ArticleId>
            <ArticleId IdType="pubmed">24800041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, et al. . 
Haemophilus influenzae infection and Guillain-Barre syndrome. Brain. 2000;123(Pt 10):2171–8. doi:10.1093/brain/123.10.2171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.10.2171</ArticleId>
            <ArticleId IdType="pubmed">11004133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Wals P Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, et al. . 
Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012;308:175–81. doi:10.1001/jama.2012.7342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2012.7342</ArticleId>
            <ArticleId IdType="pubmed">22782419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brannagan TH, 3rd Zhou Y.
HIV-associated Guillain-Barre syndrome. J Neurol Sci. 2003;208:39–42. doi:10.1016/S0022-510X(02)00418-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-510X(02)00418-5</ArticleId>
            <ArticleId IdType="pubmed">12639723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leis AA, Stokic DS.
Neuromuscular manifestations of west nile virus infection. Front Neurol. 2012;3:37. doi:10.3389/fneur.2012.00037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2012.00037</ArticleId>
            <ArticleId IdType="pmc">PMC3309965</ArticleId>
            <ArticleId IdType="pubmed">22461779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anaya JM, Rodriguez Y, Monsalve DM, Vega D, Ojeda E, Gonzalez-Bravo D, et al. . 
A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cucuta, Colombia. J Autoimmun. 2017;77:123–38. doi:10.1016/j.jaut.2016.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2016.12.007</ArticleId>
            <ArticleId IdType="pubmed">28062188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz JC, Vazquez-Calvo A, Blazquez AB, Merino-Ramos T, Escribano-Romero E, Martin-Acebes MA.
Zika Virus: the Latest Newcomer. Front Microbiol. 2016;7:496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4835484</ArticleId>
            <ArticleId IdType="pubmed">27148186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prineas JW.
Pathology of the Guillain-Barre syndrome. Ann Neurol. 1981;9(Suppl):6–19. doi:10.1002/ana.410090704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410090704</ArticleId>
            <ArticleId IdType="pubmed">7224616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP.
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30:131–56. doi:10.1002/mus.20076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20076</ArticleId>
            <ArticleId IdType="pubmed">15266629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brechenmacher C, Vital C, Deminiere C, Laurentjoye L, Castaing Y, Gbikpi-Benissan G, et al. . 
Guillain-Barre syndrome: an ultrastructural study of peripheral nerve in 65 patients. Clin Neuropathol. 1987;6:19–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3552352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csurhes PA, Sullivan AA, Green K, Pender MP, McCombe PA.
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1431–9. doi:10.1136/jnnp.2004.052282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2004.052282</ArticleId>
            <ArticleId IdType="pmc">PMC1739377</ArticleId>
            <ArticleId IdType="pubmed">16170091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCombe PA, Csurhes PA.
T cells from patients with Guillain-Barre syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. J Clin Neurosci
2010;17:537–8. doi:10.1016/j.jocn.2009.07.096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2009.07.096</ArticleId>
            <ArticleId IdType="pubmed">20093028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi LJ, Wang HB, Zhang Y, Wang WZ.
Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol. 2007;192:206–14. doi:10.1016/j.jneuroim.2007.09.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2007.09.034</ArticleId>
            <ArticleId IdType="pubmed">17997492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harness J, McCombe PA.
Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barre syndrome patients compared to controls. J Clin Neurosci. 2008;15:1031–5. doi:10.1016/j.jocn.2007.09.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2007.09.016</ArticleId>
            <ArticleId IdType="pubmed">18653346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ubogu EE.
Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathol. 2015;130:445–68. doi:10.1007/s00401-015-1466-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-015-1466-4</ArticleId>
            <ArticleId IdType="pmc">PMC4575885</ArticleId>
            <ArticleId IdType="pubmed">26264608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia RH, Yosef N, Ubogu EE.
Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome. J Neuroimmunol. 2010;219:54–63. doi:10.1016/j.jneuroim.2009.11.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.11.019</ArticleId>
            <ArticleId IdType="pubmed">20034679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC.
Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015;1852:658–66. doi:10.1016/j.bbadis.2014.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2014.06.013</ArticleId>
            <ArticleId IdType="pubmed">24949885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rinaldi S.
Update on Guillain-Barre syndrome. J Peripher Nerv Syst. 2013;18:99–112. doi:10.1111/jns5.12020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jns5.12020</ArticleId>
            <ArticleId IdType="pubmed">23781958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. . 
Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35. doi:10.1002/ana.410390512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410390512</ArticleId>
            <ArticleId IdType="pubmed">8619548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nyland H, Matre R, Mork S.
Immunological characterization of sural nerve biopsies from patients with Guillain-Barre syndrome. Ann Neurol. 1981;9(Suppl):80–6. doi:10.1002/ana.410090713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410090713</ArticleId>
            <ArticleId IdType="pubmed">7224617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Putzu GA, Figarella-Branger D, Bouvier-Labit C, Liprandi A, Bianco N, Pellissier JF.
Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J Neurol Sci. 2000;174:16–21. doi:10.1016/S0022-510X(99)00328-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-510X(99)00328-7</ArticleId>
            <ArticleId IdType="pubmed">10704976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zweiman B, Rostami A, Lisak RP, Moskovitz AR, Pleasure DE.
Immune reactions to P2 protein in human inflammatory demyelinative neuropathies. Neurology. 1983;33:234–7. doi:10.1212/WNL.33.2.234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.33.2.234</ArticleId>
            <ArticleId IdType="pubmed">6600513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inglis HR, Csurhes PA, McCombe PA.
Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:419–22. doi:10.1136/jnnp.2006.106617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.106617</ArticleId>
            <ArticleId IdType="pmc">PMC2077767</ArticleId>
            <ArticleId IdType="pubmed">17158557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makowska A, Pritchard J, Sanvito L, Gregson N, Peakman M, Hayday A, et al. . 
Immune responses to myelin proteins in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2008;79:664–71. doi:10.1136/jnnp.2007.123943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.123943</ArticleId>
            <ArticleId IdType="pubmed">17717020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziganshin RH, Ivanova OM, Lomakin YA, Belogurov AA, Jr., Kovalchuk SI, Azarkin IV, et al. . 
The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids. Mol Cell Proteomics. 2016;15:2366–78. doi:10.1074/mcp.M115.056036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M115.056036</ArticleId>
            <ArticleId IdType="pmc">PMC4937510</ArticleId>
            <ArticleId IdType="pubmed">27143409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, et al. . 
Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barre syndrome. J Neurocytol. 1996;25:33–51. doi:10.1007/BF02284784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02284784</ArticleId>
            <ArticleId IdType="pubmed">8852937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, et al. . 
Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635–44. doi:10.1002/ana.410400414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410400414</ArticleId>
            <ArticleId IdType="pubmed">8871584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, et al. . 
Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol. 2012;233:534–42. doi:10.1016/j.expneurol.2011.11.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2011.11.039</ArticleId>
            <ArticleId IdType="pmc">PMC3268874</ArticleId>
            <ArticleId IdType="pubmed">22178332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ.
The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst. 2005;10:94–112. doi:10.1111/j.1085-9489.2005.0010202.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1085-9489.2005.0010202.x</ArticleId>
            <ArticleId IdType="pubmed">15958123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N.
Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000;48:624–31. doi:10.1002/1531-8249(200010)48:4%3c624::AID-ANA9%3e3.0.CO;2-O.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200010)48:4%3c624::AID-ANA9%3e3.0.CO;2-O</ArticleId>
            <ArticleId IdType="pubmed">11026446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H, et al. . 
Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology. 1998;51:371–8. doi:10.1212/WNL.51.2.371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.51.2.371</ArticleId>
            <ArticleId IdType="pubmed">9710005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ.
Ganglioside complexes: new autoantibody targets in Guillain-Barre syndromes. Nat Clin Pract Neurol. 2005;1:2–3. doi:10.1038/ncpneuro0001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0001</ArticleId>
            <ArticleId IdType="pubmed">16932482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ, Goodyear CS.
Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol. 2013;34:453–9. doi:10.1016/j.it.2013.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2013.05.001</ArticleId>
            <ArticleId IdType="pubmed">23770405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, et al. . 
Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barre syndrome. J Neuroimmunol. 2008;194:181–90. doi:10.1016/j.jneuroim.2007.11.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2007.11.017</ArticleId>
            <ArticleId IdType="pubmed">18178257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, et al. . 
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol. 1996;40:181–7. doi:10.1002/ana.410400209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410400209</ArticleId>
            <ArticleId IdType="pubmed">8773599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. . 
Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205:101–4. doi:10.1016/j.jneuroim.2008.09.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2008.09.016</ArticleId>
            <ArticleId IdType="pubmed">18973956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, et al. . 
Patterns of recovery in the Guillain-Barre syndromes. Neurology. 1997;48:695–700. doi:10.1212/WNL.48.3.695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.48.3.695</ArticleId>
            <ArticleId IdType="pubmed">9065550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwabara S, Bostock H, Ogawara K, Sung JY, Kanai K, Mori M, et al. . 
The refractory period of transmission is impaired in axonal Guillain-Barre syndrome. Muscle Nerve. 2003;28:683–9. doi:10.1002/mus.10488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.10488</ArticleId>
            <ArticleId IdType="pubmed">14639581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WJ, et al. . 
Acute "axonal" Guillain-Barre polyneuropathy. Neurology. 1987;37:357. doi:10.1212/WNL.37.2.357-b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.37.2.357-b</ArticleId>
            <ArticleId IdType="pubmed">3808327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolter T.
Ganglioside biochemistry. ISRN Biochem. 2012;2012:506160. doi:10.5402/2012/506160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5402/2012/506160</ArticleId>
            <ArticleId IdType="pmc">PMC4393008</ArticleId>
            <ArticleId IdType="pubmed">25969757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I.
Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997;745:32–6. doi:10.1016/S0006-8993(96)01123-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-8993(96)01123-7</ArticleId>
            <ArticleId IdType="pubmed">9037391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JX, Willison HJ, Pedrosa-Domellof F.
Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci. 2009;50:3226–32. doi:10.1167/iovs.08-3333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.08-3333</ArticleId>
            <ArticleId IdType="pubmed">19255160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba A, Kusunoki S, Shimizu T, Kanazawa I.
Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–9. doi:10.1002/ana.410310619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410310619</ArticleId>
            <ArticleId IdType="pubmed">1514781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Kuwabara S.
Fisher syndrome. Curr Treat Options Neurol
2011;13:71–8. doi:10.1007/s11940-010-0103-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11940-010-0103-8</ArticleId>
            <ArticleId IdType="pubmed">21104459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ.
Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126:2220–34. doi:10.1093/brain/awg235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg235</ArticleId>
            <ArticleId IdType="pubmed">12876146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overell JR, Willison HJ.
Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol. 2005;18:562–6. doi:10.1097/01.wco.0000173284.25581.2f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.wco.0000173284.25581.2f</ArticleId>
            <ArticleId IdType="pubmed">16155441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaida K, Kusunoki S.
Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: mini-review. J Neuroimmunol. 2010;223:5–12. doi:10.1016/j.jneuroim.2010.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2010.02.001</ArticleId>
            <ArticleId IdType="pubmed">20172612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleyweg RP, van der Meche FG, Meulstee J.
Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology. 1988;38:1639–41. doi:10.1212/WNL.38.10.1639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.38.10.1639</ArticleId>
            <ArticleId IdType="pubmed">2458549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plasmapheresis and acute Guillain-Barre syndrome 
The Guillain-Barre syndrome Study Group. Neurology. 1985;35:1096–104. doi:10.1212/WNL.35.8.1096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.35.8.1096</ArticleId>
            <ArticleId IdType="pubmed">4022342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Meche FG, Schmitz PI.
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–9. doi:10.1056/NEJM199204233261705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199204233261705</ArticleId>
            <ArticleId IdType="pubmed">1552913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plasma exchange in Guillain-Barre syndrome: one-year follow-up 
French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol. 1992;32:94–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1642477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome 
Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9014908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer zu Horste G, Hartung HP, Kieseier BC.
From bench to bedside–experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol. 2007;3:198–211. doi:10.1038/ncpneuro0452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0452</ArticleId>
            <ArticleId IdType="pubmed">17410107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubinstein MA, Kagan BM, Macgillviray MH, Merliss R, Sacks H.
Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med. 1959;51:1409–19. doi:10.7326/0003-4819-51-6-1409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-51-6-1409</ArticleId>
            <ArticleId IdType="pubmed">14439917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C.
Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978;2:1100. doi:10.1016/S0140-6736(78)91837-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(78)91837-8</ArticleId>
            <ArticleId IdType="pubmed">82118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids 
French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol. 1987;22:753–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2893583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. . 
Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736–40. doi:10.1212/WNL.61.6.736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.61.6.736</ArticleId>
            <ArticleId IdType="pubmed">14504313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A.
Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294–300. doi:10.1212/WNL.0b013e318207b1f6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318207b1f6</ArticleId>
            <ArticleId IdType="pmc">PMC3034395</ArticleId>
            <ArticleId IdType="pubmed">21242498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donofrio PD.
Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve. 2003;28:273–92. doi:10.1002/mus.10402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.10402</ArticleId>
            <ArticleId IdType="pubmed">12929187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Appropriate number of plasma exchanges in Guillain-Barre syndrome 
The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol. 1997;41:298–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9066350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raphael JC, Chevret S, Hughes RA, Annane D.
Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2002;2:CD001798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12076424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroder A, Linker RA, Gold R.
Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009;9:1331–9. doi:10.1586/ern.09.81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/ern.09.81</ArticleId>
            <ArticleId IdType="pubmed">19769448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esperou H, Jars-Guincestre MC, Bolgert F, Raphael JC, Durand-Zaleski I.
Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Intensive Care Med. 2000;26:1094–100. doi:10.1007/s001340051323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s001340051323</ArticleId>
            <ArticleId IdType="pubmed">11030166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, et al. . 
Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;2:1296–9. doi:10.1016/S0140-6736(84)90819-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(84)90819-5</ArticleId>
            <ArticleId IdType="pubmed">6150321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA.
Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245–57. doi:10.1093/brain/awm004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awm004</ArticleId>
            <ArticleId IdType="pubmed">17337484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, van Doorn PA.
Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;9:CD002063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6781841</ArticleId>
            <ArticleId IdType="pubmed">25238327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. . 
Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol. 2009;66:597–603. doi:10.1002/ana.21737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21737</ArticleId>
            <ArticleId IdType="pubmed">19938102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchwald B, Ahangari R, Weishaupt A, Toyka KV.
Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002;51:673–80. doi:10.1002/ana.10205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10205</ArticleId>
            <ArticleId IdType="pubmed">12112071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Lopez PH, Li CY, Mehta NR, Griffin JW, Schnaar RL, et al. . 
Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain. 2004;127:1085–100. doi:10.1093/brain/awh127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awh127</ArticleId>
            <ArticleId IdType="pubmed">14985267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC.
Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004; 291:2367–75. doi:10.1001/jama.291.19.2367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.291.19.2367</ArticleId>
            <ArticleId IdType="pubmed">15150209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC.
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177–93. doi:10.1016/j.pharmthera.2004.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2004.04.002</ArticleId>
            <ArticleId IdType="pubmed">15246245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I.
Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barre syndrome. Lancet. 1997; 350:1747. doi:10.1016/S0140-6736(97)24050-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(97)24050-X</ArticleId>
            <ArticleId IdType="pubmed">9413468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, van Doorn PA.
Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2010;2:CD001446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20166061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Brassington R, Gunn AA, van Doorn PA.
Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2016;10:CD001446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6464149</ArticleId>
            <ArticleId IdType="pubmed">27775812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA, et al. . 
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363:192–6. doi:10.1016/S0140-6736(03)15324-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)15324-X</ArticleId>
            <ArticleId IdType="pubmed">14738791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pritchard J, Hughes RA, Hadden RD, Brassington R.
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2016;11:CD008630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6464710</ArticleId>
            <ArticleId IdType="pubmed">27846348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wollinsky KH, Hulser PJ, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann KH, et al. . 
CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial. Neurology. 2001;57:774–80. doi:10.1212/WNL.57.5.774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.57.5.774</ArticleId>
            <ArticleId IdType="pubmed">11552002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Creange A, Lerat H, Meyrignac C, Degos JD, Gherardi RK, Cesaro P.
Treatment of Guillain-Barre syndrome with interferon-beta. Lancet. 1998;352:368–9. doi:10.1016/S0140-6736(05)60466-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)60466-7</ArticleId>
            <ArticleId IdType="pubmed">9717927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al. . 
A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. Neurology. 2003;61:1282–4. doi:10.1212/01.WNL.0000092019.53628.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000092019.53628.88</ArticleId>
            <ArticleId IdType="pubmed">14610140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaller B, Radziwill AJ, Steck AJ.
Successful treatment of Guillain-Barre syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. Eur Neurol. 2001;46:167–8. doi:10.1159/000050798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000050798</ArticleId>
            <ArticleId IdType="pubmed">11598343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ.
Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study. Eur J Neurol. 2000;7:423–6. doi:10.1046/j.1468-1331.2000.00096.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1468-1331.2000.00096.x</ArticleId>
            <ArticleId IdType="pubmed">10971602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Xia J, Ye H.
Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000;20:332–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11789240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, et al. . 
Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22:4–12. doi:10.1111/jns.12194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jns.12194</ArticleId>
            <ArticleId IdType="pubmed">27801990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, et al. . 
A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barre Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Res Protoc. 2016;5:e210. doi:10.2196/resprot.6610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2196/resprot.6610</ArticleId>
            <ArticleId IdType="pmc">PMC5118582</ArticleId>
            <ArticleId IdType="pubmed">27821382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motamed-Gorji N, Matin N, Tabatabaie O, Pavone P, Romano C, Falsaperla R, et al. . 
Biological Drugs in Guillain-Barre Syndrome: An Update. Curr Neuropharmacol. 2017;15:938–50. doi:10.2174/1570159X14666161213114904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X14666161213114904</ArticleId>
            <ArticleId IdType="pmc">PMC5652014</ArticleId>
            <ArticleId IdType="pubmed">27964705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HL, Zheng XY, Zhu J.
Th1/Th2/Th17/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev. 2013;24:443–53. doi:10.1016/j.cytogfr.2013.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2013.05.005</ArticleId>
            <ArticleId IdType="pubmed">23791985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong C, Palladino SP, Helton ES, Ubogu EE.
The pathogenic relevance of alphaM-integrin in Guillain-Barre syndrome. Acta Neuropathol. 2016;132:739–52. doi:10.1007/s00401-016-1599-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-016-1599-0</ArticleId>
            <ArticleId IdType="pmc">PMC5074851</ArticleId>
            <ArticleId IdType="pubmed">27460017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller WA.
Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 2003;24:327–34. doi:10.1016/S1471-4906(03)00117-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1471-4906(03)00117-0</ArticleId>
            <ArticleId IdType="pubmed">12810109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Man S, Ubogu EE, Ransohoff RM.
Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 2007;17:243–50. doi:10.1111/j.1750-3639.2007.00067.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1750-3639.2007.00067.x</ArticleId>
            <ArticleId IdType="pubmed">17388955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchi E, Molteni R, Pardi R, Dubini G.
Microfluidics for in vitro biomimetic shear stress-dependent leukocyte adhesion assays. J Biomech. 2013;46:276–83. doi:10.1016/j.jbiomech.2012.10.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbiomech.2012.10.024</ArticleId>
            <ArticleId IdType="pubmed">23200903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang S, Ubogu EE.
The role of chemokines in Guillain-Barre syndrome. Muscle Nerve. 2013;48:320–30. doi:10.1002/mus.23829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23829</ArticleId>
            <ArticleId IdType="pmc">PMC4024180</ArticleId>
            <ArticleId IdType="pubmed">23447114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan F, Yosef N, Lakshmana Reddy C, Huang A, Chiang SC, Tithi HR, et al. . 
CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome. PLoS One. 2014;9:e90463. doi:10.1371/journal.pone.0090463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0090463</ArticleId>
            <ArticleId IdType="pmc">PMC3954548</ArticleId>
            <ArticleId IdType="pubmed">24632828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yosef N, Ubogu EE.
alpha(M)beta(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barre syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro. J Cell Physiol. 2012;227:3857–75. doi:10.1002/jcp.24100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.24100</ArticleId>
            <ArticleId IdType="pmc">PMC3414653</ArticleId>
            <ArticleId IdType="pubmed">22552879</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
